UTHR - GlaxoSmithKline the latest drugmaker to restrict discounts under 340B program

GlaxoSmithKline (GSK +1.7%) has joined a long list of pharmaceutical companies that will limit its medications purchased at prices under the federal government's 340B drug discount program to certain safety net hospital covered entities. In a letter sent Monday, GSK (GSK +1.7%) said that beginning April 1, "GSK will ship products purchased at the 340B price exclusively to locations registered as a 340B covered entity or child site location affiliated with that covered entity. Covered entity contract pharmacies will no longer be eligible recipients." Other pharmas that have 340B restrictions already in place are: AbbVie (ABBV +1.4%), Amgen (AMGN -0.9%), AstraZeneca (AZN +4.3%), Bristol-Myers Squibb (BMY +1.2%), Eli Lilly (LLY +3.6%), Merck (MRK +1.8%), Novartis (NVS +0.7%), Novo Nordisk (NVO +3.6%), Sanofi(SNY +1.6%), UCB (OTCPK:UCBJF) and United Therapeutics (UTHR +0.4%). The U.S. Department of Health and Human Services in September 2021 threatened drugmakers with fines for refusing to appropriately comply with

For further details see:

GlaxoSmithKline the latest drugmaker to restrict discounts under 340B program